ZNF133 antibody - N-terminal region (ARP35674_P050)
- Known as:
- ZNF133 (anti-) - N-terminal region (ARP35674_P050)
- Catalog number:
- arp35674_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- ZNF133 antibody - N-terminal region (ARP35674_P050)
Ask about this productRelated genes to: ZNF133 antibody - N-terminal region (ARP35674_P050)
- Gene:
- ZNF133 NIH gene
- Name:
- zinc finger protein 133
- Previous symbol:
- ZNF150
- Synonyms:
- pHZ-13, pHZ-66
- Chromosome:
- 20p11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1993-02-11
- Date modifiied:
- 2014-11-18
Related products to: ZNF133 antibody - N-terminal region (ARP35674_P050)
Related articles to: ZNF133 antibody - N-terminal region (ARP35674_P050)
- Valsartan, an angiotensin II receptor blocker, is widely used for hypertension and heart failure. While its cardiovascular benefits are established, its broader pharmacological effects remain incompletely characterized. This study aimed to identify genetic variants associated with valsartan use and to systematically explore its potential effects and adverse events across a wide range of phenotypes. - Source: PubMed
Publication date: 2026/03/20
Zeng ShengyinLi YaxinZhang YucongLu YueqiRuan LeiZhang CuntaiZhang JianguoChen BangweiLi Tao - Detection of important genes affecting lung adenocarcinoma (LUAD) is critical to finding effective therapeutic targets for this highly lethal cancer. However, many existing approaches have focused on single outcomes or phenotypic associations, which may not be as thorough as investigating molecular transcript levels within cells. In this article, we apply a novel multivariate rank-distance correlation-based gene selection procedure (MrDcGene) to LUAD multi-omics data downloaded from The Cancer Genome Atlas (TCGA). MrDcGene provides additional opportunities for detecting novel susceptibility genes as it leverages information from multiple platforms, while efficiently handling challenges such as high dimensionality, low signal-to-noise ratio, unknown distributions, and non-linear structures, etc. Notably, the MrDcGene method is able to detect two different scenarios, i.e., strong association strength with a few gene expressions and weak association strength with several gene expressions. After thoroughly exploring the association between gene expression (GE) and multiple other platforms, including reverse phase protein array (RPPA), miRNA, copy number variation (CNV) and DNA methylation (ME), we detect several novel genes that may play an important role in LUAD (ZNF133, CCDC159, YWHAZ, HNRNPR. ITPR2, PTHLH, and WIPI2). In addition, we quantitatively validate several other susceptibility genes that were reported in the literature using different methods and studies. The accuracy of the MrDcGene approach is theoretically assured and empirically demonstrated by the simulation studies. - Source: PubMed
Publication date: 2024/08/03
Zhao ShaofeiQi CalebZhao GeranWang YangshengFu Guifang - The etiology of sex differences in the risk of asthma-COPD phenotype and COPD is still not completely understood. Genetic and environmental risk factors are commonly believed to play an important role. This study aims to identify sex-specific genetic markers associated with asthma-COPD phenotype and COPD using the Canadian Longitudinal Study on Aging (CLSA) Baseline Comprehensive and Genomic data. There were a total of 1,415 COPD cases. Out of them, 504 asthma-COPD phenotype cases were identified. 20,524 participants without a diagnosis of asthma and COPD served as controls. We performed genome-wide SNP-by-sex interaction analysis. SNPs with an interaction p-value < 10 were included in a sex-stratified multivariable logistic regression for asthma-COPD phenotype and COPD outcomes. 18 and 28 SNPs had a significant interaction term p-value < 10 with sex in the regression analyses of asthma-COPD phenotype and COPD outcomes, respectively. Sex-stratified multivariable analysis of asthma-COPD phenotype showed that 7 SNPs in/near SMYD3, FHIT, ZNF608, RIMBP2, ZNF133, BPIFB1, and S100B loci were significant in males. Sex-stratified multivariable analysis of COPD showed that 8 SNPs in/near MAGI1, COX18, OSTC, ELOVL5, C7orf72 FGF14, and NKAIN4 were significant in males, and 4 SNPs in/near genes CAMTA1, SATB2, PDE10A, and LINC00908 were significant in females. An SNP in the ZPBP gene was associated with COPD in both males and females. Identification of sex-specific loci associated with asthma-COPD phenotype and COPD may offer valuable evidence toward a better understanding of the sex-specific differences in the pathophysiology of the diseases. - Source: PubMed
Odimba UgochukwuSenthilselvan AmbikaipakanFarrell JamieGao Zhiwei - Due to the complexity and heterogeneity of breast cancer, the therapeutic effects of breast cancer treatment vary between subtypes. Breast cancer subtypes are classified based on the presence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2. Thus, novel, comprehensive, and precise molecular indicators in breast carcinogenesis are urgently needed. Here, we report that ZNF133, a zinc-finger protein, is negatively associated with poor survival and advanced pathological staging of breast carcinomas. Moreover, ZNF133 is a transcription repressor physically associated with the KAP1 complex. It transcriptionally represses a cohort of genes, including L1CAM, that are critically involved in cell proliferation and motility. We also demonstrate that the ZNF133/KAP1 complex inhibits the proliferation and invasion of breast cancer cells in vitro and suppresses breast cancer growth and metastasis in vivo by dampening the transcription of L1CAM. Taken together, the findings of our study confirm the value of ZNF133 and L1CAM levels in the diagnosis and prognosis of breast cancer, contribute to a deeper understanding of the regulation mechanism of ZNF133 for the first time, and provide a new therapeutic strategy and precise intervention target for breast cancer. - Source: PubMed
Publication date: 2023/05/23
Li LifangWang XuefeiHu KaiLiu XinhuaQiu LiBai ChangsenCui YanfenWang BiyunWang ZhaosongWang HailongCheng RunfenHua JialeiHai LinyueWang MengdieLiu MiaoSong ZianXiao ChunhuaLi Binghui - The genetic etiology of sporadic childhood cancer cases remains unclear. We recruited a cohort of 20 patients who survived a childhood malignancy and then developed a second primary cancer (2N), and 20 carefully matched patients who survived a childhood cancer without developing a second malignancy (1N). Twenty matched cancer-free (0N) and additional 1000 (0N) GHS participants served as controls. Aiming to identify new candidate loci for cancer predisposition, we compared the genome-wide DNA copy number variations (CNV) with the RNA-expression data obtained after in vitro irradiation of primary fibroblasts. In 2N patients, we detected a total of 142 genes affected by CNV. A total of 53 genes of these were not altered in controls. Six genes (POLR3F, SEC23B, ZNF133, C16orf45, RRN3, and NTAN1) that we found to be overexpressed after irradiation were also duplicated in the genome of the 2N patients. For the 1N collective, 185 genes were affected by CNV and 38 of these genes were not altered in controls. Five genes (ZCWPW2, SYNCRIP, DHX30, DHRS4L2, and THSD1) were located in duplicated genomic regions and exhibited altered RNA expression after irradiation. One gene (ABCC6) was partially duplicated in one 1N and one 2N patient. Analysis of methylation levels of THSD1 and GSTT2 genes which were detected in duplicated regions and are frequently aberrantly methylated in cancer showed no changes in patient's fibroblasts. In summary, we describe rare and radiation-sensitive genes affected by CNV in childhood sporadic cancer cases, which may have an impact on cancer development. KEY MESSAGES: • Rare CNV's may have an impact on cancer development in sporadic, non-familial, non-syndromic childhood cancer cases. • In our cohort, each patient displayed a unique pattern of cancer-related gene CNVs, and only few cases shared similar CNV. • Genes that are transcriptionally regulated after radiation can be located in CNVs in cancer patients and controls. • THSD1 and GSTT2 methylation is not altered by CNV. - Source: PubMed
Publication date: 2020/06/23
Danuta GaletzkaTobias MüllerMarcus DittrichMiriam EndresNergiz KartalOlesja SinizynSteffen RappTanja ZellerChristian MüllerThomas HankelnPeter Scholz-KreiselHeather ChorzempaJohanna MirschAlicia PoplawskiHeidi RossmannClaudia SpixThomas HaafDirk PrawittManuela MarronHeinz Schmidberger